Breaking News, Collaborations & Alliances

ExcellGene, Bharat Biotech & University of Sydney to Develop Variant-Proof SARS-CoV-2 Vaccine

ExcellGene to produce complex chimeric Spike antigens using its engineered CHOExpress-cell based technology.

Author Image

By: Charlie Sternberg

Associate Editor

ExcellGene SA, privately held and founded 2001, has announced its role in the recently approved consortium funding through the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership of public, private, philanthropic and civil society organizations founded to develop vaccines against future epidemics.   The consortium partnership strives to advance a new vaccine concept that confers highly cross-reactive protection against numerous SARS-CoV-2 variants of concern (VoCs) as ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters